Business context and reporting period
Hain Celestial Group, Inc. markets and manufactures organic, natural and “better-for-you” food, beverage, poultry/protein and personal-care products in more than 80 countries. The supplied filing is the Form 10-K for the fiscal year ended June 30, 2017, not a fiscal 2016 Q4 filing. It includes unaudited quarterly results for the three months ended June 30, 2017.
Key financial results
Amounts below are in U.S. dollars. Fiscal 2017 comparisons are with fiscal 2016 unless stated otherwise.
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net sales | $2,853.1 million | $2,885.4 million |
| Gross profit / margin | $541.4 million / 19.0% | $614.1 million / 21.3% |
| Operating income / margin | $110.8 million / 3.9% | $150.4 million / 5.2% |
| Net income | $67.4 million | $47.4 million |
| Diluted EPS | $0.65 | $0.46 |
| Adjusted EBITDA | $275.4 million | $379.1 million |
| Cash from operating activities | $216.6 million | $206.6 million |
| Operating free cash flow | $153.5 million | $129.3 million |
| Cash and cash equivalents at year-end | $147.0 million | $127.9 million |
| Total debt and borrowings | $750.1 million | $862.7 million |
| Working capital | $534.3 million | $543.2 million |
Material changes versus the prior period
- Reported net sales declined 1.1%; excluding a $124.3 million adverse foreign-exchange impact, sales increased 3.2% on a constant-currency basis. Growth on that basis was primarily supported by acquisitions and U.K. and Rest-of-World performance.
- Gross margin fell 230 basis points, and operating income declined 26.3%. The company cited pricing and trade investment, customer/product mix, U.K. production costs, Orchard House margin dilution and FreeBird poultry-facility startup costs.
- Net income and diluted EPS rose from FY2016, which had substantial impairment charges and a higher effective tax rate. Adjusted EBITDA, by contrast, fell 27.3%.
- Hain Pure Protein operating income dropped to $1.4 million from $31.6 million, reflecting production inefficiencies, prior-year poultry-market conditions and new-facility startup costs. U.S. operating income fell 22.6%; U.K. operating income fell 29.0%.
- Debt declined by approximately $112.5 million, while operating cash flow increased. Capital expenditures were $63.1 million, down from $77.3 million.
Quarter, outlook, risks and unusual items
- FY2017 fourth-quarter net sales were $725.1 million; operating income was $8.6 million and net income was $0.3 million. The quarter included $14.1 million of tradename impairment, $26.4 million of long-lived asset impairment—primarily tied to exiting portions of U.K. own-label chilled desserts—and $9.5 million of accounting-review professional fees.
- Management expected approximately $75 million of FY2018 capital expenditures, with possible additional Project Terra costs. Project Terra identified global cost savings over the following three fiscal years, but the filing does not provide a clear quantified savings target. The company planned to reinvest part of savings in brands and shift U.S. trade spending toward consumer-facing activities.
- Management stated cash, projected operating cash flows and available credit were expected to fund ordinary working-capital needs, anticipated FY2018 capital expenditures and other expected cash requirements for at least 12 months. The $1.0 billion revolving facility expires in December 2019; $260.1 million was available at June 30, 2017, and the company reported covenant compliance.
- Material reporting-control concerns: management identified material weaknesses in the control environment, IT general and dependent controls, and revenue-recognition controls. Management judged disclosure controls and internal control over financial reporting ineffective; Ernst & Young issued an adverse opinion on internal control, while issuing an unqualified opinion on the financial statements. Remediation was underway but not yet demonstrated effective.
- The SEC had issued a subpoena in January 2017 concerning its investigation, including the accounting review and delayed filings. Securities class actions and derivative litigation were pending; outcomes and potential costs were uncertain.
- The filing reported Nasdaq continued-listing compliance issues related to the delayed 2016 annual meeting, and ineligibility to use Form S-3 until June 2018 at the earliest. Other key exposures include foreign exchange, commodity and ingredient costs, customer/distributor concentration, competition, acquisitions and goodwill impairment. Goodwill was approximately $1.06 billion; the Hain Daniels reporting unit had limited headroom in the impairment analysis.
- The board authorized up to $250 million of share repurchases in June 2017; none was repurchased under the program by fiscal year-end. No cash dividend was anticipated in the foreseeable future.
Important facts for investors to verify
- Confirm the filing period: this is FY2017, despite the request metadata referring to 2016 Q4.
- Track remediation and independent testing of the disclosed material weaknesses, particularly revenue recognition and IT controls.
- Monitor SEC-investigation and shareholder-litigation developments, including any financial exposure or effects on listing and capital-raising access.
- Assess whether margins and Hain Pure Protein profitability recover, and whether Project Terra savings offset cost pressures without weakening brand investment.
- Review cash generation, debt repayment, covenant headroom and the use of the authorized buyback alongside acquisition and capital-spending needs.
- Evaluate foreign-exchange sensitivity, commodity inflation and impairment risk, especially for Hain Daniels and other acquired brands.